Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors

SAR and QSAR in Environmental Research

Volumn 22, Issue 3-4, 2011, Pages 239-263

  Gupta, A K ^a   Bhunia, S S ^a   Balaramnavar, V M ^a   Saxena, A K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Discovery studio; Docking; EGFR tyrosine kinase; HER 1; Pharmacophore; Virtual screening

Indexed keywords

DIAGNOSIS; ENZYMES; HYDROGEN BONDS; MOLECULES; PHARMACODYNAMICS;

DISCOVERY STUDIO; DOCKING; EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE; EPIDERMAL GROWTH FACTOR RECEPTORS; HER 1; PHARMACOPHORE MODELS; PHARMACOPHORES; RECEPTOR-TYROSINE KINASE; TYROSINE KINASE INHIBITOR; VIRTUAL SCREENING;

AMINO ACIDS;

EID: 79957875786     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2010.548830     Document Type: Article

References (50)

1. J.D. Jordan, E.M. Landau, and R. Iyengar, Signaling networks: The origins of cellular multitasking, Cell 103 (2000), pp. 193-200.
2. K.M. Ferguson, M.B. Berger, J.M. Mendrola, H.S. Cho, D.J. Leahy, and M.A. Lemmon, EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization, Mol. Cell 11 (2003), pp. 507-517.
3. M.A. Olayioye, I. Beuvink, K. Horsch, J.M. Daly, and N.E. Hynes, ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases, J. Biol. Chem. 274 (1999), pp. 17209-17218.
4. C.T. Guy, R.D. Cardiff, and W.J. Muller, Activated neu induces rapid tumor progression, J. Biol. Chem. 271 (1996), pp. 7673-7678.
5. M.A. Olayioye, R.M. Neve, H.A. Lane, and N.E. Hynes, The ErbB signaling network: Receptor heterodimerization in development and cancer, EMBO J. 19 (2000), pp. 3159-3167.
6. T. Moriki, H. Maruyama, and I.N. Maruyama, Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain, J. Mol. Biol. 311 (2000), pp. 1011-1026.
7. X. Yu, K.D. Sharma, T. Takahashi, R. Iwamoto, and E. Mekada, Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling, Mol. Biol. Cell 13 (2002), pp. 2547-2557.
8. A. Sorokin, Activation of the EGF receptor by insertional mutations in its juxtamembrane regions, Oncogene 11 (1995), pp. 1531-1540.
9. A. Levitzki and A. Gazit, Tyrosine kinase inhibition: An approach to drug development, Science 267 (1995), pp. 1782-1788.
10. D.W. Fry, Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors, Exp. Opin. Invest. Drugs 3 (1994), pp. 577-595.
11. P. Traxler, Protein tyrosine kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents 7 (1997), pp. 571-588.
12. P. Bonomi, Erlotinib: A new therapeutic approach for non-small cell lung cancer, Exp. Rev. Anticancer Ther. 3 (2003), pp. 367-380.
13. J. Baker, K.H. Gibson, W. Grudy, A.A. Godfrey, J.J. Barlow, M.P. Healy, J.R. Woodburn, S.E. Ashton, B.J. Curry, L. Scarlett, L. Henthorn, and L. Richards, Studies leading to the identification of ZD1839 (iressaTM): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer, Bioorg. Med. Chem. Lett. 11 (2001), pp. 1911-1914.
14. D.W. Rusnak, K. Lackey, E.R. Wood, K.J. Alligood, N. Rhodes, W.B. Knight, and T.M. Gilmer, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo, Mol. Cancer Ther. 1 (2001), pp. 85-94.
15. N. Yoshimuraa, S. Kudoha, T. Kimuraa, S. Mitsuokaa, K. Matsuuraa, K. Hirataa, K. Matsuib, S. Negoroc, K. Nakagawad, and M. Fukuokad, EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib, Lung Cancer 51 (2006), pp. 363-368.
16. A. Wissner, E. Overbeek, M.F. Reich, M.B. Floyd, B.D. Johnson, N. Mamuya, E.C. Rosfjord, C. Discafani, R. Davis, X. Shi, S.K. Rabindran, B.C. Gruber, F. Ye, W.A. Hallett, R. Nilakantan, R. Shen, Y.F. Wang, L.M. Greenberger, and H.R. Tsou, Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2), J. Med. Chem. 46 (2003), pp. 49-63.
17. W.H. Ward, P.N. Cook, A.M. Slater, D.H. Davies, G.A. Holdgate, and L.R. Green, Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor, Biochem. Pharmacol. 48 (1994), pp. 659-666.
18. D.W. Fry, A.J. Kraker, A. McMichael, L.A. Ambroso, J.M. Nelson, W.R. Leopold, R.W. Connors, and A.J. Bridges, A specific inhibitor of the epidermal growth factor receptor tyrosine kinase, Science 265 (1994), pp. 1093-1095.
19. G.W. Rewcastle, W.A. Denny, A.J. Bridges, H. Zhou, D.R. Cody, A. McMichael, and D.W. Fry, Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 50-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor, J. Med. Chem. 38 (1995), pp. 3482-3487.
20. G.W. Rewcastle, B.D. Palmer, A.J. Bridges, H.D. Showalter, L. Sun, J.M. Nelson, A. McMichael, A.J. Kraker, D.W. Fry, and W.A. Denny, Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor, J. Med. Chem. 39 (1996), pp. 918-928.
21. A.M. Thompson, A.J. Bridges, D.W. Fry, A.J. Kraker, and W.A. Denny, Tyrosine kinase inhibitors:7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)-amino]pyrido[4,3- d]pyrimidines: A new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor, J. Med. Chem. 38 (1995), pp. 3780-3788.
22. P. Traxler, P. Furet, H. Mett, E. Buchdunger, T. Meyer, and N. Lydon, 4-(Phenylamino) pyrrolopyrim-idines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase, J. Med. Chem. 39 (1996), pp. 2285-2292.
23. G.W. Rewcastle, A.J. Bridges, D.W. Fry, J.R. Rubin, and W.A. Denny, Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)- pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor, J. Med. Chem. 40 (1997), pp. 1820-1826.
24. P. Traxler, G. Bold, J. Frei, M. Lang, N. Lydon, H. Mett, E. Buchdunger, T. Meyer, M. Mueller, and P. Furet, Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines, J. Med. Chem. 40 (1997), pp. 3601-3616.
25. P. Traxler, J. Green, H. Mett, U. Se'quin, and P. Furet, Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1h)-quinolones, J. Med. Chem. 42 (1999), pp. 1018-1026.
26. B.D. Palmer, S. Trumpp-Kallmeyer, D.W. Fry, J.M. Nelson, H.D. Showalter, and W.A. Denny, Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding, J. Med. Chem. 40 (1997), pp. 1519-1529.
27. S. Trumpp-Kallmeyer, J.R. Rubin, C. Humblet, J.M. Hamby, and H.D. Hollis Showalter, Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors, J. Med. Chem. 41 (1998), pp. 1752-1763.
28. H.D. Hollis Showalter, A.J. Bridges, H. Zhou, A.D. Sercel, A. McMichael, and D.W. Fry, Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5-b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase, J. Med. Chem. 42 (1999), pp. 5464-5474.
29. L.L. Zhu, T.J. Hou, L.R. Chen, and X.J. Xu, 3D QSAR analyses of novel tyrosine kinase inhibitors based on pharmacophore alignment, J. Chem. Inf. Comput. Sci. 41 (2001), pp. 1032-1040.
30. R. Gundla, R. Kazemi, R. Sanam, R. Muttineni, A.J. Sarma, R. Dayam, and N. Neamati, Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: Combined ligand and target-based approach, J. Med. Chem. 51 (2008), pp. 3367-3377.
31. C.L. Motta, S. Sartini, T. Tuccinardi, E. Nerini, F. Da Settimo, and A. Martinelli, Computational studies of epidermal growth factor receptor: Docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies, J. Med. Chem. 52 (2009), pp. 964-975.
32. F.A. Pasha, M. Muddassar, A.K. Srivastava, and S.J. Cho, In silico QSAR studies of anilinoquinolines as EGFR inhibitors, J. Mol. Model. 16 (2010), pp. 263-277.
33. H. Assefa, S. Kamath, and J.K. Buolamwini, 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, J. Comp. Aided Mol. Des. 17 (2003), pp. 475-493.
34. D.V. Pednekar, M.A. Kelkar, S.R. Pimple, and K.G. Akamanchi, 3D QSAR studies of inhibitors of epidermal growth factor receptor [EGFR] using CoMFA and GFA methodologies, Med. Chem. Res. 13 (2004), pp. 605-618.
35. R. Lin, S.G. Johnson, P.J. Connolly, S.K. Wetter, E. Binnun, T.V. Hughes, W.V. Murray, N.B. Pandey, S.J. Moreno-Mazza, M. Adams, and A.R. Fuentes-Pesquera, Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, Bioorg. Med. Chem. Lett. 19 (2009), pp. 2333-2337.
36. H.F. Van Brocklin, J.K. Lim, S.L. Coffing, D.L. Hom, K. Negash, M.Y. Ono, J.L. Gilmore, I. Bryant, and D.J. Riese II, Anilinodialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes, J. Med. Chem. 48 (2005), pp. 7445-7456.
37. A.G. Waterson, K.G. Petrov, K.R. Hornberger, R.D. Hubbard, D.M. Sammond, S.C. Smith, H.D. Dickson, T.R. Caferro, K.W. Hinkle, K.L. Stevens, S.H. Dickerson, D.W. Rusnak, G.M. Spehar, E.R. Wood, R.J. Griffin, and D.E. Uehling, Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors, Bioorg. Med. Chem. Lett. 19 (2009), pp. 1332-1336.
38. S.G. Kim, C.J. Yoon, S.H. Kim, Y.J. Cho, and D.I. Kang, Building a common feature hypothesis for thymidylate synthase inhibition, Bioorg. Med. Chem. 8 (2000), pp. 11-17.
39. Li, J. Sutter, and R. Hoffmann, HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models. In Pharmacophore Perception, Development and Use in Drug Design, International University Line, La Jolla, CA, 2000.
40. Discovery Studio 2.0; Accelrys: 9685 Scranton Road, San Diego, CA 92121, USA.
41. R. Fischer, The Principle of Experimentation, Illustrated by a Psycho-physical Experiment. In the Design of Experiments, Hafner Publishing Co., New York, 1966.
42. T.R. Rheault, T.R. Caferro, S.H. Dickerson, K.H. Donaldson, M.D. Gaul, A.S. Goetz, R.J. Mullin, O.B. McDonald, K.G. Petrov, D.W. Rusnak, L.M. Shewchuk, G.M. Spehar, A.T. Truesdale, D.E. Vanderwall, E.R. Wood, and D.E. Uehling, Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors, Bioorg. Med. Chem. Lett. 19 (2009), pp. 817-820.
43. M. Pannala, S. Kher, N. Wilson, J. Gaudette, I. Sircar, S. Zhang, A. Bakhirev, G. Yang, P. Yuen, F. Gorcsan, N. Sakurai, M. Barbosab, and J. Cheng, Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 5978-5982.
44. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, A. Cunningham, C. DiOrio, J. Doty, M.J. Morin, M.P. Moyer, M. Neveu, V.A. Pollack, L.R. Pustilnik, M.M. Reynolds, D. Sloan, A. Theleman, and P. Miller, Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase, Cancer Res. 57 (1997), pp. 4838-4848.
45. D.W. Rusnak, K. Lackey, K. Affleck, E.R. Wood, K.J. Alligood, N. Rhodes, B.R. Keith, D.M. Murray, W.B. Knight, R.J. Mullin, and T.M. Gilmer, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo, Mol. Cancer Ther. 1 (2001), pp. 85-94.
46. D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L.R. Chirieac, R.F. Padera, G.I. Shapiro, A. Baum, F. Himmelsbach, W.J. Rettig, M. Meyerson, F. Solca, H. Greulich, and K.K. Wong, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene 27 (2008), pp. 4702-4711.
47. L.F. Allen, I.A. Eiseman, D.W. Fry, and P.F. Lenehan, CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer, Semin. Oncol. 30 (2003), pp. 65-78.
48. A.J. Bridges, H. Zhou, D.R. Cody, G.W. Rewcastle, A. McMichael, H.D. Showalter, D.W. Fry, A.J. Kraker, and W.A. Denny, Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor, J. Med. Chem. 39 (1996), pp. 267-276.
49. M. Bos, J. Mendelsohn, Y.M. Kim, J. Albanell, D.W. Fry, and J. Baselga, PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner, Clin. Cancer Res. 3 (1997), pp. 2099-2106.
50. Glide, version 5.5, Schrodinger, LLC, New York, NY, 2009.